Overview
Galatea Bio builds diverse genomic data to power precision health. It operates three offerings: GB Community for diverse biobanking (starting with the Biobank of the Americas), GB Discovery to develop algorithms and drug targets from that data, and GB Health a clinical lab that delivers actionable genomic results to clinics and pharma partners. The company analyzes DNA data from underrepresented populations to find genetic associations and translate them into new drug targets and clinical tests. Its goal is to reduce health disparities by expanding diversity in genomic datasets and speeding up discoveries and actionable insights for healthcare and drug development.
Work here?Claim your company
Simplify's take
What believers are saying
- A 2026 investor page still highlights NIH-funded grants and active headquarters growth.
- March 2025 funding raised $25 million to map 10 million people.
- The 2025 ACMG launch expanded revenue opportunities in lab workflows and risk reporting.
What critics are saying
- The company promised 10 million samples by 2026, yet public pages showed 500,000 in 2024.
- PRS products face clinical validation scrutiny from payers, labs, and ACMG reviewers.
- If biobank growth stalls, Galatea becomes a niche testing vendor, not a defensible genomics platform.
What makes Galatea Bio unique
- Galatea’s Biobank of the Americas targets non-European genomes at continent scale.
- StrataRisk turns diverse-ancestry PRS into SaaS for clinical labs.
- Partnerships with Stanford, CZI, DNAnexus, and iHope deepen data and distribution.
Help us improve and share your feedback! Did you find this helpful?